Arrowhead Pharmaceuticals Inc. (ARWR)
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through its TRiM, or Targeted RNAi Molecule, platform.
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near
Arrowhead Pharmaceuticals NASDAQ: ARWR is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead
Arrowhead Pharmaceuticals transitions from a 'show-me' pipeline to commercial stage, with its first approval for plozasiran in FCS. ARWR's valuation reflects a 5% downside, 10-15% base case upside, and up to 40% bull case upside, supporting a cautious buy rating. The investment thesis centers on a robust RNAi platform, late-stage cardiometabolic franchise, and significant near-term catalysts, notably SHTG phase 3 data.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million?
CEO Christopher Anzalone sold 85,000 shares in the open market on Dec. 17, 2025, for a transaction value of ~$5,443,462. This sale represented 2.17% of Mr.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript
Arrowhead Pharmaceuticals, Inc. ( ARWR ) TD Cowen Treatment Advancements in Obesity and Related Disorders Summit November 24, 2025 1:30 PM EST Company Participants James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Everyone, and thank you for joining us at TD Cowen's 2025 Treatment Advances in Obesity Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. ( ARWR ) Q4 2025 Earnings Call November 25, 2025 4:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise James Hamilton - Chief Medical Officer and Head of R&D Daniel Apel - Chief Financial Officer Conference Call Participants Luca Issi - RBC Capital Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Dina Ramadane - BofA Securities, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Madison Wynne El-Saadi - B.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript
Arrowhead Pharmaceuticals, Inc. ( ARWR ) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome November 18, 2025 1:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce Given Conference Call Participants Ryan Mcelroy - Leerink Partners LLC, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Farzin Haque - Jefferies LLC, Research Division Luca Issi - RBC Capital Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Avraham Novick - Morgan Stanley, Research Division Chi Meng Fong - BofA Securities, Research Division John Peyton Bohnsack - TD Cowen, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division William Pickering - Sanford C.
